Core Points - BeiGene announced the grant of a total of 36,000 restricted stock units to 237 grantees under the 2016 option and incentive plan [1] - Additionally, one grantee was awarded a total of 2,935 performance stock units [1] - The total restricted stock units and performance stock units correspond to 509,197 shares, representing approximately 0.03% of the company's total issued shares as of the announcement date [1]

Core Points - BeiGene (06160) announced that on September 30, 2025, the Board's Compensation Committee granted a total of 36,000 restricted stock units involving American Depositary Shares to 237 grantees under the 2016 Option and Incentive Plan [1] - Additionally, one grantee was awarded 2,935 performance stock units involving American Depositary Shares [1]

Core Viewpoint - BeiGene (06160.HK) announced the grant of restricted stock units and performance stock units to 237 recipients, totaling 36,000 American Depositary Shares (ADS) [1] Summary by Categories - **Stock Grants** - The board's compensation committee granted a total of 36,000 restricted stock units to 237 recipients [1] - Additionally, one recipient was awarded 2,935 performance stock units [1] - **Equity Impact** - The restricted stock units and performance stock units correspond to 509,197 shares, which represents approximately 0.03% of the company's total issued shares as of the announcement date [1]

Core Viewpoint - BeiGene (06160) announced the grant of restricted stock units and performance stock units to its employees as part of its 2016 option and incentive plan, indicating ongoing commitment to employee incentives and retention [1] Summary by Categories Company Actions - The board's compensation committee granted a total of 36,000 American Depositary Shares (ADS) in restricted stock units to 237 grantees [1] - Additionally, one grantee received 2,935 ADS in performance stock units [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 百濟神州有限公司 (根據瑞士法律註冊成立的公司) 呈交日期: 2025年10月8日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06160 | 說明 | 請見備注 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 2,311,463,847 | USD | | 0.0001 USD | | 231,146.38 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 2,311,463,847 | USD | | 0.0001 USD | | 231,146.38 | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 BeOne Medicines Ltd. 百濟神州有限公司 （根據瑞士法律註冊成立的公司） （股份代號：06160） 授出受限制股份單位及業績股份單位 本公告乃根據上市規則第17.06A、17.06B以及17.06C條作出。於2025年9月30 日，董事會薪酬委員會根據2016期權及激勵計劃的條款向二百三十七名承授人授 出涉及合共36,234股美國存託股份的受限制股份單位，並向一名承授人授出涉及 合共2,935股美國存託股份的業績股份單位。 2016期權及激勵計劃項下的受限制股份單位及業績股份單位 於2025年9月30日，董事會薪酬委員會根據2016期權及激勵計劃的條款授予二百 三十七名承授人合共36,234股美國存託股份受限制股份單位，並向一名承授人授 出合共2,935股美國存託股份業績股份單位。該等受限制股份單位及業績股份單位 相當於509,197股股份，約佔本公告之日公司發行股份總數的0.03%。 ...

Core Viewpoint - Pharmacyclics LLC has decided not to appeal the final written decision from the USPTO regarding the patent dispute with BeiGene, leading to the voluntary withdrawal of the lawsuit by both parties [1][4]. Group 1: Legal Proceedings - On June 13, 2023, Pharmacyclics filed a lawsuit against BeiGene and its subsidiary BeOne Medicines USA, claiming that the product Brukinsa infringed on its US patent No. 11,672,803 [4]. - The court agreed to suspend the infringement lawsuit pending the outcome of BeiGene's application for a post-grant review (PGR) of the '803 patent, which is due by November 1, 2023 [4]. - On April 29, 2025, the USPTO declared the '803 patent invalid, and Pharmacyclics had the option to appeal this decision [4][5]. Group 2: Financial Performance - In the first half of 2025, BeiGene reported total revenue of 17.518 billion yuan, a year-on-year increase of 46.0%, and achieved a net profit of 450 million yuan, compared to a loss of 2.877 billion yuan in the same period last year [7]. - The majority of BeiGene's revenue came from international markets, with overseas sales of Brukinsa reaching 11.335 billion yuan, accounting for 65.3% of total revenue, while sales in China were 1.192 billion yuan [7]. Group 3: Historical Financials - From 2017 to 2020, BeiGene experienced significant net losses, with figures of 982 million yuan, 4.747 billion yuan, 6.915 billion yuan, and 11.384 billion yuan respectively [5]. - The company continued to incur losses from 2021 to 2023, with net losses of 9.748 billion yuan, 13.642 billion yuan, and 6.716 billion yuan [5].

智通财经APP获悉，Global X中国生物科技ETF(02820) 8月份录得正回报。未来资产表示，在全球化主 题延续、国内政策支持、企业盈利改善及宏观环境向好的共同推动下，中国生物科技板块仍是年内表现 最佳的领域。近期重大对外授权交易彰显全球对中国企业创新质量的认可。我们发现过去两年对外授权 交易数量及首付款金额呈加速增长趋势，且创新药占比持续提升，表明中国原研资产进入美国/全球市 场正成为生物科技领域新常态。生物科技企业盈利改善和商业化进程加速，有望提振投资者对中国医疗 健康板块的情绪。 百济神州2025年第二季度业绩表现稳健：营收13亿美元（环比+18%），净利润9430万美元，双双超市 场预期。明星产品BRUKINSA（泽布替尼）的强劲销售势头（尤其在海外市场）推动当期利润率扩 张。公司同步上调了2025年营收指引下限和毛利率指引。（公司数据，2025 年 8 月） 江苏恒瑞医药（01276 ） 恒瑞医药8月公布的2025年第二季度业绩符合预期：当期营收86亿元人民币（同比+12.5%），药品销售 额约71亿元（同比+15%），较一季度11%的同比增速有所提升；净利润26亿元（同比+25%）。公司上 ...

A 股代码：688235 A 股简称：百济神州 公告编号：2025-036 港股代码：06160 港股简称：百济神州 美股代码：ONC 百济神州有限公司 关于公司涉及诉讼的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、本次诉讼的基本情况及最新进展 2023 年 6 月 13 日，Pharmacyclics LLC 公司（作为申诉方，以下简称 "Pharmacyclics"）在美国特拉华州地方法院对百济神州有限公司（以下简称 "公司"）及公司全资子公司 BeOne Medicines USA, Inc（. 前称 BeiGene USA, Inc.） （作为被申诉方）提出申诉，声称公司产品百悦泽®侵犯了其于 2023 年 6 月 13 日授权的美国专利编号为 11,672,803 的专利（以下简称"'803 专利"），并请 1 案件所处的诉讼阶段：双方已向法院提交一份共同协议，自愿撤回案件， 案件已做出终局处理。 公司所处的当事人地位：本次诉讼的被申诉方。 是否会对公司损益产生负面影响：本次诉讼 ...

Market Overview - The Hang Seng Index (HSI) closed at 26,857.70, down by 100.07 points or 0.37% as of October 7, 16:00 Eastern Time [1] - The index reached a high of 27,169.45 and a low of 26,849.11 during the trading session, with a trading volume of 47.63 million [1] - The HSI's 52-week high is 27,275.90 and the low is 18,856.77, indicating a trading range of 1.19% [1] Blue-Chip Stocks Performance - Major blue-chip stocks mostly declined, with HSBC Holdings closing at HKD 110.069, down 0.75% from the Hong Kong market close [2] - Tencent Holdings closed at HKD 670.363, down 1.05% compared to the Hong Kong market close [2] Individual Stock Movements - Tencent Holdings (00700) saw a slight increase of 0.59% to HKD 677.500, but its ADR price was HKD 670.363, reflecting a decrease of 7.137 [3] - Alibaba Group (09988) decreased by 2.49% to HKD 180.500, with its ADR price at HKD 176.415, down by 4.085 [3] - HSBC Holdings (00005) increased by 0.91% to HKD 110.900, while its ADR price was HKD 110.069, down by 0.831 [3] - Other notable declines include Xiaomi Group (01810) down 2.09% to HKD 53.850 and JD.com (09618) down 2.14% to HKD 137.200 [3]